Interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic
sclerosis (SSc), which is also known as scleroderma. Two randomized clinical trials in …

Objective The course of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is
highly variable and different from continuously progressive idiopathic pulmonary fibrosis …

Pulmonary involvement is second in frequency only to esophageal involvement as a visceral
complication of systemic sclerosis (SSc) and has surpassed renal involvement as the most …

Interstitial lung disease (ILD) is the primary cause of death in patients with systemic sclerosis
(SSc). It is thought that chronic inflammation is a key component in SSc-ILD. Treatment, such …

Objective Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis
(SSc). Although early identification and treatment of alveolitis may prevent deterioration of …

Systemic sclerosis (SSc) is a multi‐system disease characterized by skin fibrosis and
visceral disease. Therapy is organ and pathogenesis targeted. In this review, we describe …

Background Mounting evidence indicates that inflammatory mechanisms drive systemic
sclerosis (SSc) vasculopathy and fibrosis, especially early in the disease. Therefore, patients …

Pulmonary disease is the most common cause of death in patients with systemic sclerosis.
This article discusses the variety of ways the lung is affected in systemic sclerosis. These …

The purpose of the study was to examine prospectively the efficacy and safety of the
combination of intravenous pulses of cyclophosphamide and methylprednizolone, in the …

The association of cyclophosphamide (CYC) and prednisone (PRED) for the treatment of
lung fibrosis in systemic sclerosis (SSc) was only evaluated in uncontrolled studies …